Edity Therapeutics

I'm an ambitious, hard-working person, with inter-disciplinary product and business development experience in the fields of genetics and computer-science. I'm a true team- player, combining scientific depth and curiosity, vast know-how in human genetics, exceptional inter-personal skills and the ability to drive people to achievements.

Eyal is a serial MedTech entrepreneur. He has founded a variety of companies and serves as an executive director on the boards of several startups. Eyal is a Founder and Executive Director at Clear-Cut Medical Ltd., as well as Founder and Executive Director at Pi-Cardia Ltd. Earlier in his career, Eyal was Co-founder, CFO, and Senior VP of Business Development at TopSpin Medical Inc., as well as Founder, CEO, and R&D Manager of Ad4ever Inc. Before entering the MedTech sector, Eyal was a Partner at Sigma P.C.M. Capital Markets LTD, serving over the years as Vice President, Head of Economic Department, and Head of Capital Markets Activity.

Assaf has spent his career pioneering the development of novel therapies. As a senior scientist at AbbVie, Assaf contributed to IND packages for cell therapy products against both heme and solid tumors. He has a proven track record in innovation, participating in the development of the first allogeneic CAR T-cell patent at the Weizmann Institute. Assaf also studied immune-oncology pathways during his post-doctoral research at UC Berkeley and has a robust publication record.

Ofer is a high-level strategic thinker with experience working to achieve corporate goals in a dynamic and evolving environment. Ofer has 16 years of industry experience in a variety of therapeutic areas with a strong focus in cancer immunotherapy. He worked for over a decade at Compugen, focusing on early-stage development of therapeutic candidates. He has a strong track record of success in the translational development of drug candidates from discovery to clinical testing.

Sharon is highly experienced in scientific research with more than 15 years of experience in drug discovery and development from basic research through pre-clinical studies. She possesses a deep understanding of biochemistry and design of novel therapeutics. Sharon has extensive experience and expertise in oligonucleotide design, synthesis, analytics, production, and CMC. Sharon serves as a senior director at Quark Pharmaceuticals, a company developing novel RNAi-based therapeutics. Earlier in her career, Sharon served as a project manager for several organizations in the life sciences sector.

Sandra Glucksmann is a veteran biotech executive with a strong background in science. She has served as the COO and founder of Editas Medicine, Inc, a gene editing company. Prior to that, she was SVP of R&D at Cerulean Pharma, another company she joined at its founding. She spent 13 years at Millennium Pharmaceuticals, starting as a founding scientist and later taking on senior roles in the science team before moving into an executive position with responsibility for strategic program management and operations. She currently serves on the boards of gene therapy company REGENXBIO and Scenic Biotech. She holds a PhD in molecular genetics and cell biology from the University of Chicago, and was a post-doctoral fellow at MIT.

Rick has more than 30 years of experience in biotechnology and the biopharmaceutical industry recently served as the CEO at ImmPACT Bio USA Inc. He specializes in developing oncology therapeutics and has a deep understanding of small and large molecule therapeutics, oncolytic viruses, and engineered T-cell therapies. Previously, Rick held the position of VP of Cell Therapy Research at Kite pharma where he led the research, advancing three programs to IND submission. Prior to Kite, Dr. Kendall was recruited to Amgen where he had an 18-year career and held a number of leadership positions, including serving as head of oncology research.